C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...
After listening to the enterprise AI specialist's latest earnings call, I have some concerns over where the company is headed ...
The new iteration of C3 Pharmaceuticals, Inc. announced that it executed a tailored Share Subscription Agreement (SSA) with ...
The Motley Fool on MSN2d
C3.ai's Chief Says It's a "Mathematical Certainty" That the Company Will Be Profitable. But a Closer Look at the Numbers Says Something Else.C3.ai's business has been growing, but the company continues to incur losses. Management is optimistic that profitability will come in the future. The latest quarterly results showed just a modest ...
C3.ai's growth is fairly modest given its size and the strength of the demand environment. Read why I remain neutral on AI ...
We recently published a list of 10 AI News and Analyst Ratings You Should Not Miss. Since C3.ai Inc (NYSE:AI) ranks 10th on ...
One of the biggest headwinds looming for C3.ai: whether Baker Hughes, its most important customer, extends its partnership in ...
Executives are fighting back against a federal court decision that banned them from the securities industry and ordered them ...
Cannabinoid-focused biopharmaceutical company C3 Pharmaceuticals announces a planned listing on the Canadian Securities ...
This was the stock's fourth consecutive day of gains.
Shares of C3.ai Inc. AI sank 0.26% to $23.27 Wednesday, on what proved to be an all-around grim trading session for the stock ...
Enterprises and institutions are rushing to develop an AI strategy, which will be a tailwind for these two AI stocks.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback